SWAG SSG Haematology and Lymphoma Meeting Clinical Research Network West of England SWAG SSG Haematology and Lymphoma Meeting Tuesday 21st November 2017 Research Report

Clinical Research Network & Cancer Services West ofEngland SWAG - Somerset Wiltshire Avon & Gloucestershire South West Children’s Cancer & Leukaemia Research Network

NIHR CRN High Level Objectives 2017-18 Increase number of participants into NIHR CRN portfolio studies 650,000 in England 21,477 in West of England Increase the number of studies that deliver to time and target Target 80% Increase number of commercial studies delivered through network Reduce NHS study set up times Reduce time taken to recruit first participant

Cancer specialty objective for 2017-18 Number of LCRNs achieving on-target recruitment into at least 8 of the 13 Cancer subspecialties, where "on-target" means either improving recruitment by 10% from 2016/17 or meeting the following recruitment targets per 100,000 population served:  a) Brain & CNS: 0.2; b) Breast: 8; c) Colorectal: 3; d) Paediatrics: 3; e) Gynae: 3; f) Head & Neck: 1; g) Haematology: 7; h) Lung: 4; i) Sarcoma: 0.1; j) Skin: 0.2; k) Supportive & Palliative Care and Psychosocial Oncology & Survivorship: 3; l) Upper GI: 3; m) Urology: 8.

Performance regarding 2017/18 Cancer specialty target

Haematology Studies in set up CPMS ID Project Title Site Principal Investigator 15878 OPTIMAL: Optimising Renal outcome in Myeloma renal failure - A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min North Bristol NHS Trust Whiteway, Dr Alastair 12518 CMV TCR Gene Therapy -  A Phase I Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation. University Hospitals Bristol Not Known 19879 CANC 4705 - Real world UK use of Tyrosine Kinase Inhibitors (TKIs): A Retrospective description of manaGement pathways, clinical responses and compliance with 2013 European LeukemiaNeT (ELN) recommendations for CML – the UK TARGET-CML study Mehta, Dr Priyanka 30145 CANC 5476 - A Phase 1 Non-randomized/2 Randomized Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogenic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies Griffin, Dr James 30792 CATALYST - A single arm open labeled multicentre phase 1b dose escalation study of carfilzomib taken in combination with Thalidomide and Dexamethasone in relapsed AL amyloidosis Bird, Dr Jenny 33204 MUK nine a: screening study - An observational and screening study to identify high risk myeloma patients suitable for novel treatment approaches and determine treatment outcomes for non-high risk myeloma patients 33205 MUK nine b: OPTIMUM - A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.

Lymphoma Studies in set up CPMS ID Project Title Site Principal Investigator 19626 ENRICH - Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma Gloucestershire Hospitals Lush, Dr Richard Royal United Hospitals Bath Knechtli, Dr Christopher 34767 PETReA - Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma University Hospitals Bristol Robinson, Dr Stephen

Useful links https://www.crn.nihr.ac.uk/ National and local network information including training programmes templates, tools, contacts, videos etc https://odp.nihr.ac.ukOpen data platform. Look at performance across whole CRN including all specialty areas http://csg.ncri.org.uk/portfolio/portfolio-maps/ View current national portfolio of open, closed and ‘in set up’ cancer studies https://www.ukctg.nihr.ac.uk/ See where a study is open across the country http://public-odp.nihr.ac.uk/  Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

Contacts Research Delivery Manager – david.rea@nihr.ac.uk Research leads – sallymoore5@nhs.net & lisa.lowry@uhbristol.nhs.uk